Atossa Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-09$17.70 RISE2026-02-12$3.94 PEAK2026-04-20$6.17 193d | -77.7% 126d | Missed | Missed | — | — | +56.6% 67d | Missed |
DROP2025-05-14$15.45 RISE2025-08-21$11.10 PEAK2025-10-09$17.70 148d | -28.2% 99d | Missed | Missed | — | — | +59.5% 49d | Missed |
DROP2025-05-14$15.45 RISE2025-08-20$11.10 PEAK2025-10-09$17.70 148d | -28.2% 98d | Missed | Missed | — | — | +59.5% 50d | Missed |
DROP2025-05-14$15.45 RISE2025-05-29$11.40 PEAK2025-07-11$14.10 58d | -26.2% 15d | Missed | Missed | — | — | +23.7% 43d | Missed |
DROP2024-11-29$19.50 RISE2025-04-10$8.85 PEAK2025-05-14$15.45 166d | -54.6% 132d | Missed | Missed | — | — | +74.6% 34d | Missed |
DROP2024-11-29$19.50 RISE2025-04-08$8.85 PEAK2025-05-14$15.45 166d | -54.6% 130d | Missed | Missed | — | — | +74.6% 36d | Missed |
DROP2024-04-04$31.50 RISE2024-08-05$17.25 PEAK2024-09-11$22.80 160d | -45.2% 123d | Missed | Missed | — | — | +32.2% 37d | Missed |
DROP2024-04-04$31.50 RISE2024-06-25$15.45 PEAK2024-09-11$22.80 160d | -51.0% 82d | Missed | Missed | — | — | +47.6% 78d | Missed |
DROP2024-04-04$31.50 RISE2024-04-17$20.25 PEAK2024-05-06$25.80 32d | -35.7% 13d | Missed | Missed | — | — | +27.4% 19d | Missed |
DROP2023-12-28$14.70 RISE2024-01-25$12.00 PEAK2024-04-04$31.50 98d | -18.4% 28d | Missed | Missed | — | — | +162.5% 70d | Missed |
DROP2023-07-12$20.25 RISE2023-11-13$9.45 PEAK2023-12-28$14.70 169d | -53.3% 124d | Missed | Missed | — | — | +55.6% 45d | Missed |
DROP2023-01-18$13.65 RISE2023-05-01$9.00 PEAK2023-07-12$20.25 175d | -34.1% 103d | Missed | Missed | — | — | +125.0% 72d | Missed |
DROP2023-01-18$13.65 RISE2023-04-26$9.00 PEAK2023-07-12$20.25 175d | -34.1% 98d | Missed | Missed | — | — | +125.0% 77d | Missed |
DROP2022-11-02$13.80 RISE2023-03-15$9.75 PEAK2023-05-25$14.55 204d | -29.3% 133d | Missed | Missed | — | — | +49.2% 71d | Missed |
DROP2022-10-31$14.85 RISE2023-03-13$9.75 PEAK2023-05-25$14.55 206d | -34.3% 133d | Missed | Missed | — | — | +49.2% 73d | Missed |
1–15 / 25 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) researchSEATTLE, May 20, 2026 /PRNewswire/ --
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research May 19, 2026 4:00 PM EDTCompany...
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY TrialsSEATTLE, May 14, 2026 /PRNewswire/ -- Atossa
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.94) by 19.35 percent. This is a 344 percent decrease over losses of $(0.25) per share
Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is...
Atossa Therapeutics Inc: Atossa Therapeutics receives FDA rare pediatric disease designation for -endoxifen for McCune-Albright Syndrome...
RPD designation is granted to drug candidates intended to treat serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age. Upon approval of a qualifying marketing application,
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos, a global leader of AI-powered digital transformation today announced a significant advancement in its digital infrastructure strategy through expanded adoption of Lumen’s Network as a Service (NaaS) across its North America data centers, marking a strategic step in its digital transformation journey toward AI-ready, adaptive infrastructure. The initiative delivers greater agi
HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announces its financial results for the fourth quarter and year ended December 31, 2025 and provides an update on recent corporate developments.
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 55.22 percent. This is a 88 percent increase over losses of $(0.25) per share from
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases. The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its (Z)-endoxifen development
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need, presented an oral clinical trial update on (Z)-endoxifen at the MDA Clinical & Scientific Conference on March 11, 2026, in Orlando, FL.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare disease indications with significant unmet need,
SEC.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows:
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATOS | -1.88% | +16.22% | -40.90% | -55.30% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -4.85% | +21.94% | -37.46% | -67.99% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-08 | -1.22 | -1.11 | +9.02% |
| 2026-03-25 | -1.14 | -1.34 | -17.20% |
| 2025-11-12 | -1.00 | -1.05 | -5.00% |
| 2025-08-12 | -0.85 | -1.05 | -23.53% |
| 2025-05-13 | -0.82 | -0.75 | +9.09% |
| 2025-03-25 | -0.95 | -0.75 | +21.05% |
| 2024-11-12 | -0.90 | -0.90 | — |
| 2024-08-12 | -0.90 | -0.75 | +16.67% |
| 2024-05-13 | -1.00 | -0.75 | +25.00% |
| 2024-04-01 | -0.90 | -0.90 | — |
| 2023-11-13 | -1.00 | -0.75 | +25.00% |
| 2023-08-14 | -0.90 | -1.20 | -33.33% |
| 2023-05-15 | -0.90 | -0.75 | +16.67% |
| 2023-03-22 | -0.97 | -0.90 | +7.69% |
| 2022-11-07 | -0.82 | -0.90 | -9.09% |
| 2022-08-08 | -0.90 | -0.75 | +16.67% |